{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:12:28Z","timestamp":1794928348540,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41440-025-02131-0","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:57:13Z","timestamp":1739419033000},"page":"1846-1858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of intensive versus standard blood pressure control on cardiovascular outcomes in adult patients with hypertension: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"48","author":[{"given":"Tatsuya","family":"Haze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Katsurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sakima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2131_CR1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/hr.2012.87","volume":"35","author":"A Fujiyoshi","year":"2012","unstructured":"Fujiyoshi A, Ohkubo T, Miura K, Murakami Y, Nagasawa S-y, Okamura T, et al. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res. 2012;35:947\u201353.","journal-title":"Hypertens Res"},{"key":"2131_CR2","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/HJH.0b013e328359a9f7","volume":"30","author":"N Takashima","year":"2012","unstructured":"Takashima N, Ohkubo T, Miura K, Okamura T, Murakami Y, Fujiyoshi A, et al. Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. J Hypertens. 2012;30:2299\u2013306.","journal-title":"J Hypertens"},{"key":"2131_CR3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet"},{"key":"2131_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1803180","volume":"381","author":"AC Flint","year":"2019","unstructured":"Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019;381:243\u201351.","journal-title":"N Engl J Med"},{"key":"2131_CR5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"2131_CR6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775\u201381.","journal-title":"JAMA Cardiol"},{"key":"2131_CR7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","volume":"178","author":"M Brunstr\u00f6m","year":"2018","unstructured":"Brunstr\u00f6m M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178:28\u201336.","journal-title":"JAMA Intern Med"},{"key":"2131_CR8","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/HJH.0000000000001787","volume":"36","author":"C Thomopoulos","year":"2018","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 \u2013 benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. J Hypertens. 2018;36:1622\u201336.","journal-title":"J Hypertens"},{"key":"2131_CR9","doi-asserted-by":"crossref","first-page":"m3222","DOI":"10.1136\/bmj.m3222","volume":"370","author":"D Luo","year":"2020","unstructured":"Luo D, Cheng Y, Zhang H, Ba M, Chen P, Li H, et al. Association between high blood pressure and long term cardiovascular events in young adults: systematic review and meta-analysis. BMJ. 2020;370:m3222.","journal-title":"BMJ"},{"key":"2131_CR10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625\u201336.","journal-title":"Lancet"},{"key":"2131_CR11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1161\/HYPERTENSIONAHA.123.21496","volume":"80","author":"Z Bidel","year":"2023","unstructured":"Bidel Z, Nazarzadeh M, Canoy D, Copland E, Gerdts E, Woodward M, et al. Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis. Hypertension. 2023;80:2293\u2013302.","journal-title":"Hypertension"},{"key":"2131_CR12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435\u201343.","journal-title":"Lancet"},{"key":"2131_CR13","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/HYPERTENSIONAHA.124.23597","volume":"81","author":"PK Whelton","year":"2024","unstructured":"Whelton PK, O\u2019Connell S, Mills KT, He J. Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis. Hypertension. 2024;81:2329\u201339.","journal-title":"Hypertension"},{"key":"2131_CR14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41440-018-0123-4","volume":"42","author":"A Sakima","year":"2019","unstructured":"Sakima A, Satonaka H, Nishida N, Yatsu K, Arima H. Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis. Hypertens Res. 2019;42:483\u201395.","journal-title":"Hypertens Res"},{"key":"2131_CR15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2131_CR16","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269\u2013324.","journal-title":"Hypertension"},{"key":"2131_CR17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary. J Am Coll Cardiol. 2018;71:2199\u2013269.","journal-title":"J Am Coll Cardiol"},{"key":"2131_CR18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"2131_CR19","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"2131_CR20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"ACCORD Study Group.","year":"2010","unstructured":"ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"2131_CR21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Sprint Research Group, Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"2131_CR22","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"The SPRINT Research Group.","year":"2021","unstructured":"The SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921\u201330.","journal-title":"N Engl J Med"},{"key":"2131_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404:245\u201355.","journal-title":"Lancet"},{"key":"2131_CR24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2131_CR25","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2131_CR26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.119.041603","volume":"140","author":"WB White","year":"2019","unstructured":"White WB, Wakefield DB, Moscufo N, Guttmann CRG, Kaplan RF, Bohannon RW, et al. Effects of Intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). Circulation. 2019;140:1626\u201335.","journal-title":"Circulation"},{"key":"2131_CR27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/hr.2010.162","volume":"33","author":"K Hayashi","year":"2010","unstructured":"Hayashi K, Saruta T, Goto Y, Ishii M, on behalf of the JSG. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res. 2010;33:1211\u201320.","journal-title":"Hypertens Res"},{"key":"2131_CR28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1291\/hypres.31.2115","volume":"31","author":"Jatos Study Group.","year":"2008","unstructured":"Jatos Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115\u201327.","journal-title":"Hypertens Res"},{"key":"2131_CR29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","volume":"56","author":"T Ogihara","year":"2010","unstructured":"Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly. Hypertension. 2010;56:196\u2013202.","journal-title":"Hypertension"},{"key":"2131_CR30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jch.12094","volume":"15","author":"Y Wei","year":"2013","unstructured":"Wei Y, Jin Z, Shen G, Zhao X, Yang W, Zhong Y, et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens. 2013;15:420\u20137.","journal-title":"J Clin Hypertens"},{"key":"2131_CR31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","volume":"374","author":"P Verdecchia","year":"2009","unstructured":"Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525\u201333.","journal-title":"Lancet"},{"key":"2131_CR32","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/hr.2012.125","volume":"35","author":"K Asayama","year":"2012","unstructured":"Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res. 2012;35:1102\u201310.","journal-title":"Hypertens Res"},{"key":"2131_CR33","doi-asserted-by":"crossref","first-page":"i708","DOI":"10.1136\/bmj.i708","volume":"352","author":"J Mant","year":"2016","unstructured":"Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke\u2014Blood Pressure) randomised controlled trial. BMJ. 2016;352:i708.","journal-title":"BMJ"},{"key":"2131_CR34","doi-asserted-by":"crossref","first-page":"e0164608","DOI":"10.1371\/journal.pone.0164608","volume":"12","author":"PM Bath","year":"2017","unstructured":"Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, et al. Intensive versus Guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot \u2018Prevention of Decline in Cognition after Stroke Trial\u2019 (PODCAST) randomised controlled trial. PLoS ONE. 2017;12:e0164608.","journal-title":"PLoS ONE"},{"key":"2131_CR35","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1161\/STROKEAHA.120.032054","volume":"52","author":"HS Markus","year":"2021","unstructured":"Markus HS, Egle M, Croall ID, Sari H, Khan U, Hassan A, et al. PRESERVE: randomized trial of intensive versus standard blood pressure control in small vessel disease. Stroke. 2021;52:2484\u201393.","journal-title":"Stroke"},{"key":"2131_CR36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","volume":"365","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939\u201346.","journal-title":"Lancet"},{"key":"2131_CR37","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","volume":"76","author":"K Kitagawa","year":"2019","unstructured":"Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol. 2019;76:1309\u201318.","journal-title":"JAMA Neurol"},{"key":"2131_CR38","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","volume":"13","author":"R Schrier","year":"2002","unstructured":"Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13:1733\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"2131_CR39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","volume":"382","author":"CS Coffey","year":"2013","unstructured":"SPS3 Study Group BO, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507\u201315.","journal-title":"Lancet"},{"key":"2131_CR40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268\u201379.","journal-title":"N Engl J Med"},{"key":"2131_CR41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group.","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703\u201313.","journal-title":"BMJ"},{"key":"2131_CR42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","volume":"363","author":"LJ Appel","year":"2010","unstructured":"Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918\u201329.","journal-title":"N Engl J Med"},{"key":"2131_CR43","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","volume":"315","author":"JD Williamson","year":"2016","unstructured":"Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 years: a randomized clinical trial. JAMA. 2016;315:2673\u201382.","journal-title":"JAMA"},{"key":"2131_CR44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41440-022-00862-y","volume":"45","author":"K Kitagawa","year":"2022","unstructured":"Kitagawa K, Arima H, Yamamoto Y, Ueda S, Rakugi H, Kohro T, et al. Intensive or standard blood pressure control in patients with a history of ischemic stroke: RESPECT post hoc analysis. Hypertens Res. 2022;45:591\u2013601.","journal-title":"Hypertens Res"},{"key":"2131_CR45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1747-4949.2010.00573.x","volume":"6","author":"OR Benavente","year":"2011","unstructured":"Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente M-F, et al. The secondary prevention of small subcortical strokes (SPS3) study. Int J Stroke. 2011;6:164\u201375.","journal-title":"Int J Stroke"},{"key":"2131_CR46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","volume":"48","author":"K Norris","year":"2006","unstructured":"Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis. 2006;48:739\u201351.","journal-title":"Am J Kidney Dis"},{"key":"2131_CR47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.7326\/M16-2966","volume":"167","author":"S Beddhu","year":"2017","unstructured":"Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, et al. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease. Ann Intern Med. 2017;167:375\u201383.","journal-title":"Ann Intern Med"},{"key":"2131_CR48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"The SPRINT MIND Investigators for the SPRINT Research Group.","year":"2019","unstructured":"The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553\u201361.","journal-title":"JAMA"},{"key":"2131_CR49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamainternmed.2013.13656","volume":"174","author":"JD Williamson","year":"2014","unstructured":"Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174:324\u201333.","journal-title":"JAMA Intern Med"},{"key":"2131_CR50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.ajkd.2017.08.021","volume":"71","author":"MV Rocco","year":"2018","unstructured":"Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, et al. Effects of intensive blood pressure treatment on acute kidney injury events in the systolic blood pressure intervention trial (SPRINT). Am J Kidney Dis. 2018;71:352\u201361.","journal-title":"Am J Kidney Dis"},{"key":"2131_CR51","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","volume":"77","author":"AP Bress","year":"2021","unstructured":"Bress AP, Greene T, Derington CG, Shen J, Xu Y, Zhang Y, et al. Patient selection for intensive blood pressure management based on benefit and adverse events. J Am Coll Cardiol. 2021;77:1977\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"2131_CR52","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/HYPERTENSIONAHA.116.07474","volume":"68","author":"JL Fleg","year":"2016","unstructured":"Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial. Hypertension. 2016;68:888\u201395.","journal-title":"Hypertension"},{"key":"2131_CR53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1474-4422(14)70224-8","volume":"13","author":"LA Pearce","year":"2014","unstructured":"Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014;13:1177\u201385.","journal-title":"Lancet Neurol"},{"key":"2131_CR54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.115.019657","volume":"133","author":"CA Peralta","year":"2016","unstructured":"Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, et al. Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke. Circulation. 2016;133:584\u201391.","journal-title":"Circulation"},{"key":"2131_CR55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/ki.2011.415","volume":"81","author":"F Ismail-Beigi","year":"2012","unstructured":"Ismail-Beigi F, Craven TE, O\u2019Connor PJ, Karl D, Calles-Escandon J, Hramiak I, et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int. 2012;81:586\u201394.","journal-title":"Kidney Int"},{"key":"2131_CR56","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s11606-014-2961-3","volume":"29","author":"KL Margolis","year":"2014","unstructured":"Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med. 2014;29:1599\u2013606.","journal-title":"J Gen Intern Med"},{"key":"2131_CR57","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.12659\/MSM.914482","volume":"25","author":"W Wu","year":"2019","unstructured":"Wu W, Liu J, Li A, Li J, Yang Y, Ye X, et al. Effect of intensive blood pressure control on carotid morphology and hemodynamics in chinese patients with hyperhomocysteinemia-type hypertension and high risk of stroke. Med Sci Monit. 2019;25:5717\u201326.","journal-title":"Med Sci Monit"},{"key":"2131_CR58","first-page":"e24","volume":"19","author":"C Lessing","year":"2010","unstructured":"Lessing C, Schmitz A, Albers B, Schrappe M. Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors. Qual Saf Health Care. 2010;19:e24.","journal-title":"Qual Saf Health Care"},{"key":"2131_CR59","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30:1735\u201345.","journal-title":"J Am Soc Nephrol"},{"key":"2131_CR60","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1253\/circj.CJ-11-0695","volume":"75","author":"T Kohro","year":"2011","unstructured":"Kohro T, Yamazaki T, Izumi T, Daida H, Kurabayashi M, Miyauchi K, et al. Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients. Circ J. 2011;75:2062\u201370.","journal-title":"Circ J"},{"key":"2131_CR61","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1751-7176.2009.00121.x","volume":"11","author":"MR Weir","year":"2009","unstructured":"Weir MR, Yeh F, Silverman A, Devereux RB, Galloway JM, Henderson JA, et al. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. J Clin Hypertens. 2009;11:540\u20138.","journal-title":"J Clin Hypertens"},{"key":"2131_CR62","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.299.14.1678","volume":"299","author":"BV Howard","year":"2008","unstructured":"Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299:1678\u201389.","journal-title":"JAMA"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02131-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02131-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02131-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:02:43Z","timestamp":1749060163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02131-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02131-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}